SVA
Sinovac Biotech Ltd
NASDAQ: SVA · HEALTHCARE · BIOTECHNOLOGY
$6.47
+0.00% today
Updated 2026-04-29
Market cap
$642.44M
P/E ratio
6.66
P/S ratio
1.83x
EPS (TTM)
$0.97
Dividend yield
850.00%
52W range
$6 – $6
Volume
—
Sinovac Biotech Ltd (SVA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
21.60%
Operating margin
42.30%
ROE
25.20%
ROA
11.50%
Debt/equity
0.04x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2004 | $6.45M | $-4.67M | 69.97% | -76.64% | -72.31% |
| 2005 | $6.45M | $-4.39M | 69.97% | -82.36% | -68.08% |
| 2006 | $15.35M | $-696033.00 | 72.44% | 2.86% | -4.53% |
| 2007 | $33.54M | $7.65M | 80.61% | 40.17% | 22.81% |
| 2008 | $46.50M | $8.01M | 78.63% | 33.95% | 17.23% |
| 2009 | $84.20M | $19.96M | 76.17% | 50.06% | 23.70% |
| 2010 | $33.40M | $-8.51M | 49.95% | -39.99% | -25.47% |
| 2011 | $56.84M | $-844000.00 | 62.83% | 5.94% | -1.48% |
| 2012 | $49.22M | $-14.85M | 61.19% | -42.98% | -30.18% |
| 2013 | $71.77M | $7.44M | 71.43% | 13.86% | 10.37% |
| 2014 | $62.93M | $-1.51M | 75.41% | 3.00% | -2.41% |
| 2015 | $67.41M | $-1.42M | 72.69% | 5.48% | -2.10% |
| 2016 | $72.43M | $-596000.00 | 69.08% | 0.70% | -0.82% |
| 2017 | $174.35M | $25.81M | 88.39% | 26.05% | 14.80% |
| 2018 | $229.65M | $21.78M | 89.23% | 19.73% | 9.48% |
| 2019 | $246.05M | $44.93M | 86.80% | 27.86% | 18.26% |
| 2020 | $510.62M | $110.37M | 86.84% | 42.23% | 21.61% |
| 2021 | $19.37B | $8.47B | 94.47% | 90.60% | 43.70% |
| 2022 | $1.49B | $113.87M | 54.15% | -31.22% | 7.63% |
| 2023 | $448.27M | $-99.92M | 59.51% | -121.96% | -22.29% |